1
|
Keche Y, Gaikwad NR, Wasnik PN, Nagpure K, Siddiqui MS, Joshi A, Dhaneria S, Dewangan G, Meher J, Das P. Analysis of Drugs Prescribed to Elderly Patients in a Tertiary Health Care Center in Raipur, Central India: An Observational Study. Cureus 2024; 16:e52770. [PMID: 38389602 PMCID: PMC10882417 DOI: 10.7759/cureus.52770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/22/2024] [Indexed: 02/24/2024] Open
Abstract
Background Most elderly patients suffer from multiple diseases and are on multiple drugs for treatment. Polypharmacy in the elderly, physiological changes with old age, changes in the pharmacokinetics and pharmacodynamic effects of many drugs, and newer drug prescription trends for diseases like diabetes and cardiovascular disease make drug prescribing in the elderly more difficult. There are many chances of drug-drug interactions with easily available over-the-counter (OTC) medications. To prevent the irrational use of drugs in the elderly, there is a need for prescription analysis studies. Prescription analysis studies will help in finding errors in prescriptions and also change trends in the use of medication among the elderly. Methodology This cross-sectional observation study was conducted on 234 elderly patients to investigate medicine use patterns among the geriatric patients attending the Medicine Outpatient Department in a tertiary care teaching hospital. Drug data were collected from the study participants after obtaining written informed consent and analysed, including demographic details, personal history, disease history, and details of the drug, including the generic name of the drug, dose and duration of therapy, and prescription pattern. The proportions of drugs prescribed for different diseases were analysed. Also, the drugs were analysed as per their pharmacological profiles. Results and interpretation A total of 1298 drug prescriptions were analysed in this study. Of the total participants, 60.26% were male, 35% were unemployed, 53% were retired, and 27% were taking OTC herbal medications. Most of the patients included in this study were suffering from diabetes, hypertension, and other comorbidities. Telmisartan and telmisartan in combination with other drugs were the most commonly encountered prescription drugs, i.e., 24% among the cardiovascular drugs. Aspirin and statins alone or in combination were the most commonly encountered prescriptions, i.e., 27.88% of the drugs used for prophylaxis of cardiovascular diseases. Conclusion This study showed a prescription pattern for the elderly and highlighted precautions to be taken with some of the prescribed drugs. As polypharmacy is observed with elderly prescriptions, possible drug interactions must be taken into account. Regular prescription analysis of drugs prescribed to the elderly will help in the appropriate and rational use of drugs.
Collapse
Affiliation(s)
- Yogendra Keche
- Pharmacology, All India Institute of Medical Sciences, Raipur, Raipur, IND
| | - Nitin R Gaikwad
- Pharmacology, All India Institute of Medical Sciences, Raipur, Raipur, IND
| | - Preetam N Wasnik
- General Medicine, All India Institute of Medical Sciences, Raipur, Raipur, IND
| | - Keshao Nagpure
- General Medicine, All India Institute of Medical Sciences, Nagpur, Nagpur, IND
| | - Md Sabah Siddiqui
- General Medicine, All India Institute of Medical Sciences, Raipur, Raipur, IND
| | - Apoorva Joshi
- Pharmacology, All India Institute of Medical Sciences, Raipur, Raipur, IND
| | - Suryaprakash Dhaneria
- Pharmacology and Therapeutics, Ruxmaniben Deepchand Gardi Medical College, Ujjain, IND
| | - Gevesh Dewangan
- General Medicine, All India Institute of Medical Sciences, Raipur, Raipur, IND
| | - Jhasaketan Meher
- General Medicine, All India Institute of Medical Sciences, Raipur, Raipur, IND
| | - Pranita Das
- General Medicine, All India Institute of Medical Sciences, Raipur, Raipur, IND
| |
Collapse
|
2
|
Bakker MH, Oldejans NA, Hugtenburg JG, van der Horst HE, Slottje P. Insomnia management in Dutch general practice: a routine care database study. Scand J Prim Health Care 2023; 41:306-316. [PMID: 37470474 PMCID: PMC10478592 DOI: 10.1080/02813432.2023.2237073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 07/11/2023] [Indexed: 07/21/2023] Open
Abstract
OBJECTIVE To explore insomnia management in general practice, with a focus on sleep medication prescription. DESIGN Descriptive analysis of anonymized routine general practice care data extracted from electronic medical records (EMRs), including demographics, free text annotations from sleep consultations and sleep medication prescriptions covering one year before up to two years after the registration of the International Classification for Primary Care (ICPC) code P06 'Sleep disturbance'. SETTING Twenty-one general practices in an urban area of the Netherlands. PATIENTS Adults (18-85 year) with a first sleep consultation with their GP. OUTCOMES Documented non-pharmacological and sleep medication treatment. RESULTS Of the 1,089 patients who consulted their general practitioner (GP) for sleep disturbance for the first time, about 50% had one more sleep consultation during the two years follow-up. Over two years including the first consultation, GPs documented a non-pharmacological intervention for 48.4% of the patients and prescribed sleep medication to 77.0%. 64.6% of the patients received a sleep medication prescription in the first consultation. Among patients receiving medication (N = 838); 59.6% received more than one prescription; 76.8% received one or more short-acting benzodiazepine receptor agonist (BZRA), 39.5% one or more unrecommended drugs and 14.7% >180 pills of BZRAs in two years. CONCLUSION Although the guidelines advocate non-pharmacological treatment and warn against unwarranted sleep medication, it is still very common in Dutch general practice to prescribe medication, even at the first sleep consultation. Prescriptions frequently include unrecommended and off-label drugs or repeated BZRA prescriptions.
Collapse
Affiliation(s)
- Mette H. Bakker
- Department of General Practice, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, the Netherlands
| | - Nina A. Oldejans
- Department of General Practice, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Jacqueline G. Hugtenburg
- Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, the Netherlands
- Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Henriëtte E. van der Horst
- Department of General Practice, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, the Netherlands
| | - Pauline Slottje
- Department of General Practice, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, the Netherlands
| |
Collapse
|
3
|
Trends in the prescription of drugs used for insomnia: an open-cohort study in Australian general practice, 2011-2018. Br J Gen Pract 2021; 71:e877-e886. [PMID: 33950853 PMCID: PMC8366783 DOI: 10.3399/bjgp.2021.0054] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 04/19/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Despite an increase in the prevalence of sleep problems, few studies have investigated changes in the prescribing of drugs that are often used to manage insomnia. AIM To explore changes in the pattern of benzodiazepine (BZD), Z-drug (zolpidem, zopiclone), and non-BZD prescriptions. DESIGN AND SETTING Open-cohort study comprising 1 773 525 patients (55 903 294 consultations) who attended one of 404 Australian general practices at least three times in two consecutive years between 2011 and 2018. METHOD Data were extracted from MedicineInsight, a database of 662 general practices in Australia. Prescription rates per 1000 consultations, the proportion of repeat prescriptions above recommendations, and the proportion of prescriptions for patients with a recent (within 2 years) recorded diagnosis of insomnia were analysed using adjusted regression models. RESULTS Rates of BZD, Z-drug, and non-BZD prescriptions were 56.6, 4.4, and 15.5 per 1000 consultations in 2011 and 41.8, 3.5, and 21.5 per 1000 consultations in 2018, respectively. Over the whole study period, temazepam represented 25.3% of the prescriptions and diazepam 21.9%. All BZD and zolpidem prescriptions declined over the whole study period (annual change varying from -1.4% to -10.8%), but non-BZD and zopiclone prescriptions increased in the same period (annual change 5.0% to 22.6%). Repeat prescriptions that exceeded recommended levels remained at <10% for all medications, except melatonin (64.5%), zolpidem (63.3%), zopiclone (31.4%), and alprazolam (13.3%). In 2018, >50% of Z-drug and melatonin prescriptions were for patients with insomnia. There was an annual increase of 0.8-5.9% in the proportion of prescriptions associated with a recently recorded diagnosis of insomnia. CONCLUSION Overall, BZD prescriptions in Australia declined between 2011 and 2018. However, the prescription of some of these drugs increased for patients with a recently recorded diagnosis of insomnia. This is concerning because of the potential adverse effects of these medications and the risk of dependence.
Collapse
|
4
|
Albanese B, Palokas M. The effectiveness of non-pharmacologic treatments compared to pharmacologic treatments in veterans with sleep disturbances: a systematic review protocol. JBI Evid Synth 2020; 19:215-221. [PMID: 33165175 DOI: 10.11124/jbisrir-d-19-00276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
OBJECTIVE The objective is to determine the effectiveness of non-pharmacologic treatments compared to pharmacologic treatments in veterans with sleep disturbances. INTRODUCTION Sleep disturbances in veterans are a common occurrence. If left untreated, these individuals are susceptible not only to accidents and injuries but long-term psychiatric and/or cardiovascular complications. INCLUSION CRITERIA This review will consider studies of veterans, aged 18 and over, with a diagnosis of sleep disturbances. This study will exclude patients with psychotic disorders, obstructive sleep apnea, or other medical illnesses causing disrupted sleep. METHODS This review will use the JBI methodology for evidence of effectiveness. The search will be limited to studies published in English after 1970. The databases to be searched include MEDLINE (PubMed), CINAHL (EBSCO), Embase (Elsevier), Scopus (Elsevier), and PsycINFO (EBSCO). The trial registers to be searched include US National Library of Medicine (ClinicalTrials.gov) and Cochrane Library. The search for unpublished studies will include ProQuest Dissertations and Theses, MedNar, and WorldWideScience. Eligible studies will undergo critical appraisal and data extraction by two independent reviewers using standardized critical appraisal instruments and a data extraction tool from JBI. Studies will be pooled in statistical meta-analysis when possible. When statistical pooling is not possible, the findings will be presented in narrative form with tables and figures. SYSTEMATIC REVIEW REGISTRATION NUMBER PROSPERO (CRD42019140804).
Collapse
Affiliation(s)
- Beau Albanese
- University of Mississippi Medical Center School of Nursing, Jackson, MS, USA.,Mississippi Centre for Evidence Based Practice: A JBI Centre of Excellence, Jackson, MS, USA
| | - Michelle Palokas
- University of Mississippi Medical Center School of Nursing, Jackson, MS, USA.,Mississippi Centre for Evidence Based Practice: A JBI Centre of Excellence, Jackson, MS, USA
| |
Collapse
|
5
|
Liu L, Jian P, Zhou Y, Zhou J, Jia L, Tang M, Zhang R, Tang Y. Is the Long-Term Use of Benzodiazepines Associated With Worse Cognition Performance in Highly Educated Older Adults? Front Psychiatry 2020; 11:595623. [PMID: 33192741 PMCID: PMC7649772 DOI: 10.3389/fpsyt.2020.595623] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 09/09/2020] [Indexed: 12/13/2022] Open
Abstract
Background: Benzodiazepines (BZD) are common medications for sedative, hypnotic, and anxiolytic that are especially prevalent in older adults. Previous studies have shown that BZD use could impair users' cognition, significantly affecting their quality of life. Past research has shown that higher education might play a protective role in the process of cognitive decline. Very few studies had examined the cognitive effects of BZD on highly educated older adults. The study aimed to explore how cognitive functions would be affected by benzodiazepines among highly educated older adults. Method: 140 older adults with an average education period of 14.8 years were included in this study. The subjects were divided into three separate groups, the long-term BZD users (≥180 days), short-term BZD users (<180 days), and non-users. Demographics and cognitive assessments for the three groups were analyzed using the analysis of variance (ANOVA), the chi-squared test, and the analysis of covariance (ANCOVA). To examine the association between BZD use and cognition a multiple linear aggression approach was used. Result: All three groups were significantly different from each other when looking at executive functioning in the Trail Making Test B (TMT-B). Compared to the control group, short-term BZD users showed significant defects in TMT-B time (p = 0.002) and TMT-B errors (p < 0.001); long-term BZD users showed significant defect on TMT-B time (p = 0.041). Compared to short-term BZD users, long-term BZD users showed significant merit on TMT-B errors (p = 0.001). No significant differences were found in other cognitive tasks that reflected general cognition, verbal memory, language fluency, and visual memory. After adjusting for demographic, increased BZD use over time was positively associated with scores for the revised Brief Visuospatial Memory Test (r = 0.377, p = 0.012). Conclusion: BZD use may be significantly associated with worse executive functioning in highly educated older adults. However, there is no association between the duration of BZD use and increased cognitive deficits in highly educated older adults. This study identified future experimental directions including potential longitudinal studies, within-subject studies comparing mood disorder patients' cognitive performance before and after onset of BZD use, and between-subject studies that directly compare BZD's effect on subjects with the same baseline of cognitive functioning.
Collapse
Affiliation(s)
- Linzi Liu
- Department of Psychiatry, The First Affiliated Hospital, China Medical University, Shenyang, China
| | - Peiying Jian
- Department of Psychology, Queen's University, Kingston, ON, Canada
| | - Yifang Zhou
- Department of Psychiatry, The First Affiliated Hospital, China Medical University, Shenyang, China.,Department of Geriatrics, The First Affiliated Hospital, China Medical University, Shenyang, China
| | - Jian Zhou
- Department of Psychiatry, The First Affiliated Hospital, China Medical University, Shenyang, China
| | - Linna Jia
- Department of Psychiatry, The First Affiliated Hospital, China Medical University, Shenyang, China
| | - Minghui Tang
- The Clinical College of Precision Medicine, Liaoning He's Medical College, Shenyang, China
| | - Rongwei Zhang
- Department of Psychiatry, The First Affiliated Hospital, China Medical University, Shenyang, China.,Department of Geriatrics, The First Affiliated Hospital, China Medical University, Shenyang, China
| | - Yanqing Tang
- Department of Psychiatry, The First Affiliated Hospital, China Medical University, Shenyang, China.,Department of Geriatrics, The First Affiliated Hospital, China Medical University, Shenyang, China
| |
Collapse
|
6
|
Bruun LD, Kjeldstadli K, Temte V, Birdal M, Bachs L, Langødegård M, Strand DH, Gaare KI, Øiestad E, Høiseth G. Detection Time of Oxazepam and Zopiclone in Urine and Oral Fluid after Experimental Oral Dosing. J Anal Toxicol 2019; 43:369-377. [DOI: 10.1093/jat/bky083] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Revised: 08/16/2018] [Indexed: 01/05/2023] Open
Affiliation(s)
- Lina Dorthea Bruun
- Department of Forensic Medicine, Oslo University Hospital, Nydalen, Oslo, Norway
| | - Kari Kjeldstadli
- Department of Pharmacology, Oslo University Hospital, Nydalen, Oslo, Norway
| | - Vidar Temte
- Department of Forensic Medicine, Oslo University Hospital, Nydalen, Oslo, Norway
| | - Morris Birdal
- Department of Forensic Medicine, Oslo University Hospital, Nydalen, Oslo, Norway
| | - Liliana Bachs
- Department of Forensic Medicine, Oslo University Hospital, Nydalen, Oslo, Norway
| | - Marit Langødegård
- Department of Forensic Medicine, Oslo University Hospital, Nydalen, Oslo, Norway
| | - Dag Helge Strand
- Department of Forensic Medicine, Oslo University Hospital, Nydalen, Oslo, Norway
| | - Kristin Irene Gaare
- Department of Forensic Medicine, Oslo University Hospital, Nydalen, Oslo, Norway
| | - Elisabeth Øiestad
- Department of Forensic Medicine, Oslo University Hospital, Nydalen, Oslo, Norway
- School of Pharmacy, University of Oslo, PO Box 1068, Blindern, Oslo, Norway
| | - Gudrun Høiseth
- Department of Forensic Medicine, Oslo University Hospital, Nydalen, Oslo, Norway
- Diakonhjemmet Hospital, Center for Psychopharmacology, Vinderen, Oslo, Norway
| |
Collapse
|
7
|
Abstract
BACKGROUND Insomnia is a major public health issue affecting between 6% to 10% of the adult population in Western countries. Eszopiclone is a hypnotic drug belonging to a newer group of hypnotic agents, known as new generation hypnotics, which was marketed as being just as effective as benzodiazepines for this condition, while being safer and having a lower risk for abuse and dependence. It is the aim of the review to integrate evidence from randomised controlled trials and to draw conclusions on eszopiclone's efficacy and safety profile, while taking methodological features and bias risks into consideration. OBJECTIVES To assess the efficacy and safety of eszopiclone for the treatment of insomnia compared to placebo or active control. SEARCH METHODS We searched the Cochrane Central Register of Controlled trials (CENTRAL), MEDLINE, Embase, PsycINFO, PSYNDEX and registry databases (WHO trials portal, ClinicalTrials.gov) with results incorporated from searches to 10 February 2016. To identify trials not registered in electronic databases, we contacted key informants and searched reference lists of identified studies. We ran an update search (21 February 2018) and have placed studies of interest in awaiting classification/ongoing studies. These will be incorporated into the next version of the review, as appropriate. SELECTION CRITERIA Parallel group randomised controlled trials (RCTs) comparing eszopiclone with either placebo or active control were included in the review. Participants were adults with insomnia, as diagnosed with a standardised diagnostic system, including primary insomnia and comorbid insomnia. DATA COLLECTION AND ANALYSIS Two authors independently extracted outcome data; one reviewer assessed trial quality and the second author cross-checked it. MAIN RESULTS A total of 14 RCTs, with 4732 participants, were included in this review covering short-term (≤ 4 weeks; 6 studies), medium-term (> 4 weeks ≤ 6 months; 6 studies) and long-term treatment (> 6 months; 2 studies) with eszopiclone. Most RCTs included in the review included participants aged between 18 and 64 years, three RCTs only included elderly participants (64 to 85 years) and one RCT included participants with a broader age range (35 to 85 years). Seven studies considered primary insomnia; the remaining studies considered secondary insomnia comorbid with depression (2), generalised anxiety (1), back pain (1), Parkinson's disease (1), rheumatoid arthritis (1) and menopausal transition (1).Meta-analytic integrations of participant-reported data on sleep efficacy outcomes demonstrated better results for eszopiclone compared to placebo: a 12-minute decrease of sleep onset latency (mean difference (MD) -11.94 min, 95% confidence interval (CI) -16.03 to -7.86; 9 studies, 2890 participants, moderate quality evidence), a 17-minute decrease of wake time after sleep onset (MD -17.02 min, 95% CI -24.89 to -9.15; 8 studies, 2295 participants, moderate quality evidence) and a 28-minute increase of total sleep time (MD 27.70 min, 95% CI 20.30 to 35.09; 10 studies, 2965 participants, moderate quality evidence). There were no significant changes from baseline to the first three nights after drug discontinuation for sleep onset latency (MD 17.00 min, 95% CI -4.29 to 38.29; 1 study, 291 participants, low quality evidence) and wake time after sleep onset (MD -6.71 min, 95% CI -21.25 to 7.83; 1 study, 291 participants, low quality evidence). Adverse events during treatment that were documented more frequently under eszopiclone compared to placebo included unpleasant taste (risk difference (RD) 0.18, 95% CI 0.14 to 0.21; 9 studies, 3787 participants), dry mouth (RD 0.04, 95% CI 0.02 to 0.06; 6 studies, 2802 participants), somnolence (RD 0.04, 95% CI 0.02 to 0.06; 8 studies, 3532 participants) and dizziness (RD 0.03, 95% CI 0.01 to 0.05; 7 studies, 2933 participants). According to the GRADE criteria, evidence was rated as being of moderate quality for sleep efficacy outcomes and adverse events and of low quality for rebound effects and next-day functioning. AUTHORS' CONCLUSIONS Eszopiclone appears to be an efficient drug with moderate effects on sleep onset and maintenance. There was no or little evidence of harm if taken as recommended. However, as certain patient subgroups were underrepresented in RCTs included in the review, findings might not have displayed the entire spectrum of possible adverse events. Further, increased caution is required in elderly individuals with cognitive and motor impairments and individuals who are at increased risk of using eszopiclone in a non-recommended way.
Collapse
Affiliation(s)
- Susanne Rösner
- Forel KlinikIslikonerstrasse 5Ellikon an der ThurSwitzerland8548
| | | | | | | | - Michael Soyka
- University of MunichPsychiatric HospitalNußbaumstr. 7MunichGermany80336
| | | |
Collapse
|
8
|
Jang Y, Song I, Oh IS, Shin JY. Twelve-year trend in the use of zolpidem and physicians’ non-compliance with recommended duration: a Korean national health insurance database study. Eur J Clin Pharmacol 2018; 75:109-117. [PMID: 30280207 DOI: 10.1007/s00228-018-2563-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Accepted: 09/21/2018] [Indexed: 11/25/2022]
Affiliation(s)
- Yunjeung Jang
- School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
| | - Inmyung Song
- School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
| | - In-Sun Oh
- School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
| | - Ju-Young Shin
- School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
| |
Collapse
|
9
|
Hjelmeland K, Gustavsen I, Øiestad EL, Øiestad ÅML, Høiseth G, Mørland J. Zopiclone concentrations in oral fluid and blood after, administration of therapeutic doses of zopiclone. Forensic Sci Int 2017; 278:177-183. [PMID: 28735217 DOI: 10.1016/j.forsciint.2017.07.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Revised: 06/16/2017] [Accepted: 07/05/2017] [Indexed: 11/17/2022]
Abstract
PURPOSE Little is known about the relationship between concentrations in oral fluid (OF) and blood for the widely prescribed hypnotic drug zopiclone. The purpose of this study was to investigate the usefulness of OF zopiclone concentrations to predict blood zopiclone concentrations in order to introduce OF testing as an alternative to more cumbersome blood testing. METHODS 16 healthy young male volunteers received capsules of either 5 or 10mg zopiclone on two different study days separated by at least one week. Blood and OF were collected simultaneously at baseline and 9 times after intake of zopiclone on each study day. In addition an OF sample was collected 24-81h after intake. Lunch was served between samples taken 2.5 and 3.5h after intake. All samples were analysed for zopiclone, and the cut-off was 10ng/ml in blood and 0.2ng/ml in OF-buffer mixture. RESULTS Zopiclone was detected in all OF samples during the study day. After 24-81h, all subjects were also positive for zopiclone in OF, except from three subjects ingesting the 5mg dose. In a single case zopiclone was detected in a baseline OF sample 14days after intake on an earlier study day. Zopiclone was detected in both OF and blood in 231 OF/blood pairs, and a significant but weak correlation between OF and blood concentration was seen (R2 of 0.30). The median (range) zopiclone OF/blood concentration ratio (ZOBCR) for all samples were 3.3 (0.8-18). The ZOBCR decreased when the OF volume increased. After 30 of 31 given doses of zopiclone, the ZOBCR was higher in samples collected before lunch than samples collected after lunch. DISCUSSION Vast intra- and interindividual differences in ZOBCR were found, and the correlation between OF and blood concentration was less pronounced than reported in former studies. In accordance with earlier studies we found a negative correlation between ZOBCR and OF volume. The ZOBCR decreases in relation to recent intake of a meal, probably because stimulated saliva production causes "dilution" of saliva. OF zopiclone concentration appeared unsuitable for estimation of blood zopiclone concentration. Due to long detection time, analysis of zopiclone in OF might be useful to detect non-recent, previous intake.
Collapse
Affiliation(s)
- Knut Hjelmeland
- Department of Forensic Sciences, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway.
| | - Ingebjørg Gustavsen
- Department of Pharmacology, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway
| | - Elisabeth Leere Øiestad
- Department of Forensic Sciences, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway; School of Pharmacy, University of Oslo, P.O. Box 1068, Blindern, N-0316 Oslo, Norway
| | - Åse Marit Leere Øiestad
- Department of Forensic Sciences, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway
| | - Gudrun Høiseth
- Department of Forensic Sciences, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway; Norwegian Centre of Addiction Research (SERAF), University of Oslo, P.O. Box 1039, Blindern, N-0315 Oslo, Norway
| | - Jørg Mørland
- Norwegian Institute of Public Health, PO Box 4404, Nydalen, N-0403 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, PO Box 1072, Blindern, N-0316 Oslo, Norway
| |
Collapse
|
10
|
Chung S, Youn S. The Optimizing Strategies for Prescription of Sleeping Pills for Insomnia Patients. SLEEP MEDICINE RESEARCH 2017. [DOI: 10.17241/smr.2017.00024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Nevriana A, Möller J, Laflamme L, Monárrez-Espino J. New, Occasional, and Frequent Use of Zolpidem or Zopiclone (Alone and in Combination) and the Risk of Injurious Road Traffic Crashes in Older Adult Drivers: A Population-Based Case-Control and Case-Crossover Study. CNS Drugs 2017; 31:711-722. [PMID: 28669021 PMCID: PMC5533809 DOI: 10.1007/s40263-017-0445-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Previous studies on the effect of zolpidem or zopiclone use on the risk of road traffic crashes (RTCs) have shown mixed results. OBJECTIVE Our objective was to determine the association between zolpidem or zopiclone use (as separate drugs or combined) and the occurrence of injurious RTCs among older adult drivers. METHODS This was a population-based matched case-control and case-crossover study based on secondary data linked together from Swedish national registers. Cases were drivers aged 50-80 years involved in a vehicle crash resulting in injuries between January 2006 and December 2009 for the case-control study (n = 27,096) and from February 2006 to December 2009 for the case-crossover study (n = 26,586). For the first design, four controls were matched to each case by sex, age, and residential area, and exposure was categorized into new, occasional, and frequent use of zolpidem only, zopiclone only, and combined zolpidem and zopiclone. For the case-crossover study, newly dispensed zolpidem or zopiclone users were assessed during the 28 days prior to the crash and compared with an equally long control period using a 12-week washout period. Matched adjusted odds ratios (OR) were computed using conditional logistic regression. RESULTS Increased ORs for all users were observed. In the case-control study, the highest odds were seen among newly initiated zolpidem-only users involved in single-vehicle crashes (adjusted OR 2.27; 95% confidence interval [CI] 1.21-4.24), followed by frequent combined zolpidem and zopiclone users [adjusted OR 2.20; CI 1.21-4.00]. In the case-crossover, newly initiated treatment with zolpidem or zopiclone showed an increased risk that was highest in the 2 weeks after the start of the treatment (OR 2.66; 95% CI 1.04-6.81). CONCLUSIONS These results provide more compelling evidence for the role of zolpidem or zopiclone in the occurrence of RTCs among older adults, not only in frequent users, but also at the beginning of treatment.
Collapse
Affiliation(s)
- Alicia Nevriana
- Department of Public Health Sciences, Widerströmska huset, Karolinska Institutet, Tomtebodavägen 18A, 17177 Stockholm, Sweden
| | - Jette Möller
- Department of Public Health Sciences, Widerströmska huset, Karolinska Institutet, Tomtebodavägen 18A, 17177 Stockholm, Sweden
| | - Lucie Laflamme
- Department of Public Health Sciences, Widerströmska huset, Karolinska Institutet, Tomtebodavägen 18A, 17177 Stockholm, Sweden
| | - Joel Monárrez-Espino
- Department of Public Health Sciences, Widerströmska huset, Karolinska Institutet, Tomtebodavägen 18A, 17177, Stockholm, Sweden.
| |
Collapse
|
12
|
Weymann D, Gladstone EJ, Smolina K, Morgan SG. Long-term sedative use among community-dwelling adults: a population-based analysis. CMAJ Open 2017; 5:E52-E60. [PMID: 28401119 PMCID: PMC5378535 DOI: 10.9778/cmajo.20160056] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Chronic use of benzodiazepines and benzodiazepine-like sedatives (z-drugs) presents substantial risks to people of all ages. We sought to assess trends in long-term sedative use among community-dwelling adults in British Columbia. METHODS Using population-based linked administrative databases, we examined longitudinal trends in age-standardized rates of sedative use among different age groups of community-dwelling adults (age ≥ 18 yr), from 2004 to 2013. For each calendar year, we classified adults as nonusers, short-term users, or long-term users of sedatives based on their patterns of sedative dispensation. For calendar year 2013, we applied cross-sectional analysis and estimated logistic regression models to identify health and socioeconomic risk factors associated with long-term sedative use. RESULTS More than half (53.4%) of long-term users of sedatives in British Columbia are between ages 18 and 64 years (young and middle-aged adults). From 2004 to 2013, long-term sedative use remained stable among adults more than 65 years of age (older adults) and increased slightly among young and middle-aged adults. Although the use of benzodiazepines decreased during the study period, the trend was offset by equal or greater increases in long-term use of z-drugs. Being an older adult, sick, poor and single were associated with increased odds of long-term sedative use. INTERPRETATION Despite efforts to stem such patterns of medication use, long-term use of sedatives increased in British Columbia between 2004 and 2013. This increase was driven largely by increased use among middle-aged adults. Future deprescribing efforts that target adults of all ages may help curb this trend.
Collapse
Affiliation(s)
- Deirdre Weymann
- University of British Columbia (Weymann, Gladstone, Smolina, Morgan), School of Population and Public Health; British Columbia Cancer Agency (Weymann), Canadian Centre for Applied Research in Cancer Control, Vancouver, BC
| | - Emilie J Gladstone
- University of British Columbia (Weymann, Gladstone, Smolina, Morgan), School of Population and Public Health; British Columbia Cancer Agency (Weymann), Canadian Centre for Applied Research in Cancer Control, Vancouver, BC
| | - Kate Smolina
- University of British Columbia (Weymann, Gladstone, Smolina, Morgan), School of Population and Public Health; British Columbia Cancer Agency (Weymann), Canadian Centre for Applied Research in Cancer Control, Vancouver, BC
| | - Steven G Morgan
- University of British Columbia (Weymann, Gladstone, Smolina, Morgan), School of Population and Public Health; British Columbia Cancer Agency (Weymann), Canadian Centre for Applied Research in Cancer Control, Vancouver, BC
| |
Collapse
|
13
|
Sakshaug S, Handal M, Hjellvik V, Berg C, Ripel Å, Gustavsen I, Mørland J, Skurtveit S. Long‐term Use of Z‐Hypnotics and Co‐medication with Benzodiazepines and Opioids. Basic Clin Pharmacol Toxicol 2016; 120:292-298. [DOI: 10.1111/bcpt.12684] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 10/03/2016] [Indexed: 11/30/2022]
Affiliation(s)
| | - Marte Handal
- Norwegian Institute of Public Health Oslo Norway
| | | | | | - Åse Ripel
- Norwegian Institute of Public Health Oslo Norway
| | | | - Jørg Mørland
- Norwegian Institute of Public Health Oslo Norway
| | - Svetlana Skurtveit
- Norwegian Institute of Public Health Oslo Norway
- Norwegian Centre for Addiction Research University of Oslo Oslo Norway
| |
Collapse
|
14
|
Salvatore S, Røislien J, Baz-Lomba JA, Bramness JG. Assessing prescription drug abuse using functional principal component analysis (FPCA) of wastewater data. Pharmacoepidemiol Drug Saf 2016; 26:320-326. [PMID: 27862608 DOI: 10.1002/pds.4127] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Revised: 08/29/2016] [Accepted: 10/16/2016] [Indexed: 11/11/2022]
Abstract
BACKGROUND Wastewater-based epidemiology is an alternative method for estimating the collective drug use in a community. We applied functional data analysis, a statistical framework developed for analysing curve data, to investigate weekly temporal patterns in wastewater measurements of three prescription drugs with known abuse potential: methadone, oxazepam and methylphenidate, comparing them to positive and negative control drugs. METHODS Sewage samples were collected in February 2014 from a wastewater treatment plant in Oslo, Norway. The weekly pattern of each drug was extracted by fitting of generalized additive models, using trigonometric functions to model the cyclic behaviour. From the weekly component, the main temporal features were then extracted using functional principal component analysis. Results are presented through the functional principal components (FPCs) and corresponding FPC scores. RESULTS Clinically, the most important weekly feature of the wastewater-based epidemiology data was the second FPC, representing the difference between average midweek level and a peak during the weekend, representing possible recreational use of a drug in the weekend. Estimated scores on this FPC indicated recreational use of methylphenidate, with a high weekend peak, but not for methadone and oxazepam. CONCLUSION The functional principal component analysis uncovered clinically important temporal features of the weekly patterns of the use of prescription drugs detected from wastewater analysis. This may be used as a post-marketing surveillance method to monitor prescription drugs with abuse potential. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Stefania Salvatore
- Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway
| | - Jo Røislien
- Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway.,Department of Health Studies, University of Stavanger, Stavanger, Norway
| | - Jose A Baz-Lomba
- Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway.,Norwegian Institute for Water Research, Oslo, Norway
| | - Jørgen G Bramness
- Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway
| |
Collapse
|
15
|
Linnet K, Gudmundsson LS, Birgisdottir FG, Sigurdsson EL, Johannsson M, Tomasdottir MO, Sigurdsson JA. Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland. BMC FAMILY PRACTICE 2016. [PMID: 27267943 DOI: 10.1186/s12875‐016‐0469‐0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
BACKGROUND The prevalence of multimorbidity is increasing worldwide, presumably leading to an increased use of medicines. During the last decades the use of hypnotic and anxiolytic benzodiazepine derivatives and related drugs has increased dramatically. These drugs are frequently prescribed for people with a sleep disorder often merely designated as "insomnia" in the medical records and lacking a clear connection with the roots of the patients' problems. Our aim was to analyse the prevalence of multimorbidity in primary healthcare in Iceland, while concurrently investigating a possible association with the prevalence and incidence of hypnotic/anxiolytic prescriptions, short-term versus chronic use. METHODS Data were retrieved from a comprehensive database of medical records from primary healthcare in Iceland to find multimorbid patients and prescriptions for hypnotics and anxiolytics, linking diagnoses (ICD-10) and prescriptions (2009-2012) to examine a possible association. Nearly 222,000 patients, 83 % being local residents in the capital area, who contacted 16 healthcare centres served in total by 140 general practitioners, were set as a reference to find the prevalence of multimorbidity as well as the prevalence and incidence of hypnotic/anxiolytic prescriptions. RESULTS The prevalence of multimorbidity in the primary care population was 35 %, lowest in the young, increasing with age up to the 80+ group where it dropped somewhat. The prevalence of hypnotic/anxiolytic prescriptions was 13.9 %. The incidence rate was 19.4 per 1000 persons per year in 2011, and 85 % of the patients prescribed hypnotics/anxiolytics were multimorbid. Compared to patients without multimorbidity, multimorbid patients were far more likely to be prescribed a hypnotic and/or an anxiolytic, OR = 14.9 (95 % CI = 14.4-15.4). CONCLUSIONS Patients with multiple chronic conditions are common in the primary care setting, and prevalence and incidence of hypnotic/anxiolytic prescriptions are high. Solely explaining use of these drugs by linear thinking, i.e. that "insomnia" leads to their prescription is probably simplistic, since the majority of patients prescribed these drugs are multimorbid having several chronic conditions which could lead to sleeping problems. However, multimorbidity as such is not an indication for hypnotics, and doctors should be urged to greater caution in their prescribing, bearing in mind non-pharmacological therapy options.
Collapse
Affiliation(s)
- Kristjan Linnet
- Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.
| | - Larus S Gudmundsson
- Clinical Quality and Services, Directorate of Health, Reykjavik, Iceland.,Faculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland.,Centre of Public Health Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Frida G Birgisdottir
- Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Emil L Sigurdsson
- Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.,Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Magnus Johannsson
- Clinical Quality and Services, Directorate of Health, Reykjavik, Iceland.,Department of Pharmacology and Toxicology, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Margret O Tomasdottir
- Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.,Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.,Faculty of Medicine, Department of Public Health and General Practice Research Unit, Norwegian University of Science and Technology, Trondheim, Norway
| | - Johann A Sigurdsson
- Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.,Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.,Faculty of Medicine, Department of Public Health and General Practice Research Unit, Norwegian University of Science and Technology, Trondheim, Norway
| |
Collapse
|
16
|
Linnet K, Gudmundsson LS, Birgisdottir FG, Sigurdsson EL, Johannsson M, Tomasdottir MO, Sigurdsson JA. Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland. BMC FAMILY PRACTICE 2016; 17:69. [PMID: 27267943 PMCID: PMC4896036 DOI: 10.1186/s12875-016-0469-0] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 06/02/2016] [Indexed: 11/10/2022]
Abstract
Background The prevalence of multimorbidity is increasing worldwide, presumably leading to an increased use of medicines. During the last decades the use of hypnotic and anxiolytic benzodiazepine derivatives and related drugs has increased dramatically. These drugs are frequently prescribed for people with a sleep disorder often merely designated as “insomnia” in the medical records and lacking a clear connection with the roots of the patients’ problems. Our aim was to analyse the prevalence of multimorbidity in primary healthcare in Iceland, while concurrently investigating a possible association with the prevalence and incidence of hypnotic/anxiolytic prescriptions, short-term versus chronic use. Methods Data were retrieved from a comprehensive database of medical records from primary healthcare in Iceland to find multimorbid patients and prescriptions for hypnotics and anxiolytics, linking diagnoses (ICD-10) and prescriptions (2009–2012) to examine a possible association. Nearly 222,000 patients, 83 % being local residents in the capital area, who contacted 16 healthcare centres served in total by 140 general practitioners, were set as a reference to find the prevalence of multimorbidity as well as the prevalence and incidence of hypnotic/anxiolytic prescriptions. Results The prevalence of multimorbidity in the primary care population was 35 %, lowest in the young, increasing with age up to the 80+ group where it dropped somewhat. The prevalence of hypnotic/anxiolytic prescriptions was 13.9 %. The incidence rate was 19.4 per 1000 persons per year in 2011, and 85 % of the patients prescribed hypnotics/anxiolytics were multimorbid. Compared to patients without multimorbidity, multimorbid patients were far more likely to be prescribed a hypnotic and/or an anxiolytic, OR = 14.9 (95 % CI = 14.4–15.4). Conclusions Patients with multiple chronic conditions are common in the primary care setting, and prevalence and incidence of hypnotic/anxiolytic prescriptions are high. Solely explaining use of these drugs by linear thinking, i.e. that “insomnia” leads to their prescription is probably simplistic, since the majority of patients prescribed these drugs are multimorbid having several chronic conditions which could lead to sleeping problems. However, multimorbidity as such is not an indication for hypnotics, and doctors should be urged to greater caution in their prescribing, bearing in mind non-pharmacological therapy options.
Collapse
Affiliation(s)
- Kristjan Linnet
- Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.
| | - Larus S Gudmundsson
- Clinical Quality and Services, Directorate of Health, Reykjavik, Iceland.,Faculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland.,Centre of Public Health Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Frida G Birgisdottir
- Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Emil L Sigurdsson
- Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.,Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Magnus Johannsson
- Clinical Quality and Services, Directorate of Health, Reykjavik, Iceland.,Department of Pharmacology and Toxicology, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Margret O Tomasdottir
- Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.,Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.,Faculty of Medicine, Department of Public Health and General Practice Research Unit, Norwegian University of Science and Technology, Trondheim, Norway
| | - Johann A Sigurdsson
- Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.,Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.,Faculty of Medicine, Department of Public Health and General Practice Research Unit, Norwegian University of Science and Technology, Trondheim, Norway
| |
Collapse
|
17
|
Tjagvad C, Clausen T, Handal M, Skurtveit S. Benzodiazepine prescription for patients in treatment for drug use disorders: a nationwide cohort study in Denmark, 2000-2010. BMC Psychiatry 2016; 16:168. [PMID: 27234965 PMCID: PMC4884346 DOI: 10.1186/s12888-016-0881-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Accepted: 05/20/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Benzodiazepines are frequently prescribed to patients with drug use disorders. However, it has previously been difficult to distinguish whether this frequent prescribing was due to underlying psychiatric disorders or inappropriate prescribing. In a nationwide cohort study, we investigated the prescribing of benzodiazepines to patients with drug use disorders in connection with treatment admission. METHODS Benzodiazepine prescriptions to patients (N = 33203) aged 18 to 67 years admitting for outpatient treatment for drug use disorders in Denmark, 2000 to 2010, were studied by using linked data from nationwide health registries. Factors associated with increasing amounts of benzodiazepine use within the first year after admission were assessed by multinomial logistic regression. Proportions of very long-term benzodiazepine prescription were calculated. RESULTS During the first year after admission to treatment, 26.2 % of patients were prescribed benzodiazepines. Of these, 35.5 % were prescribed benzodiazepines at dose levels that might indicate inappropriate use (>365 Defined Daily Dose per year), and 34.6 % were prescribed more than one type of benzodiazepines. Diazepam was the most commonly prescribed type. Among patients with opioid use, 43.2 % were prescribed benzodiazepines which were three times higher than for patients with cannabis (12.2 %) or central stimulating drugs (13.8 %) as their primary drug use. Admitting to treatment for a drug use disorder did not increase the specialized psychiatric treatment coverage of this patient group, disregarding use of prescribed benzodiazepines. 29.5 % were new users of prescribed benzodiazepines, and of these, 27.5 % continued into very long-term use (≥4 years after admission) during the study period. CONCLUSIONS Benzodiazepines were commonly prescribed to patients admitting to treatment for drug use disorders, and included prescription of multiple and non-optimal types, high doses, and very long-term prescriptions. These findings point towards inappropriate prescribing of benzodiazepines in many cases more than treatment for psychiatric disorders.
Collapse
Affiliation(s)
- Christian Tjagvad
- Norwegian Centre for Addiction Research [SERAF], University of Oslo, Kirkeveien 166, Bygg 45, 0407, Oslo, Norway.
| | - Thomas Clausen
- Norwegian Centre for Addiction Research [SERAF], University of Oslo, Kirkeveien 166, Bygg 45, 0407 Oslo, Norway
| | - Marte Handal
- Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway
| | - Svetlana Skurtveit
- Norwegian Centre for Addiction Research [SERAF], University of Oslo, Kirkeveien 166, Bygg 45, 0407 Oslo, Norway ,Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway
| |
Collapse
|
18
|
Tjagvad C, Skurtveit S, Bramness JG, Gjersing L, Gossop M, Clausen T. Misuse of prescription drugs and overdose deaths. JOURNAL OF SUBSTANCE USE 2016. [DOI: 10.3109/14659891.2015.1077280] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
19
|
Hoffmann F, Glaeske G. [Benzodiazepine hypnotics, zolpidem and zopiclone on private prescriptions: use between 1993 and 2012]. DER NERVENARZT 2015; 85:1402-9. [PMID: 24663439 DOI: 10.1007/s00115-014-4016-8] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Previous analyses showed that benzodiazepine hypnotics as well as zolpidem and zopiclone (Z drugs) were increasingly being dispensed on so-called private prescriptions (Privatverordnungen) in Germany. Any doctor can provide private prescriptions for prescription drugs which are fully funded by the patient. This study aimed to analyze the amount of private prescriptions for hypnotics over the last 20 years. METHODS We compared utilization data from statutory health insurance claims with purchasing statistics from community pharmacies for the years 1993-2012. RESULTS From 1993 to 2012 purchased packages of hypnotics decreased (from 14.9 to 9.9 million). Benzodiazepines were dispensed less and Z drugs more often. In 2012 zopiclone (4.3 million packages of which 42.7 % were private prescriptions), zolpidem (3.6 million, 57.6 %) and lormetazepam (0.8 million, 57.8 %) were most often prescribed. CONCLUSION Trends in prescribing Z drugs are particularly noticeable whereby zolpidem was dispensed more often on private prescriptions than zopiclone. This seems to be further evidence for a higher dependence and abuse potential of zolpidem.
Collapse
Affiliation(s)
- F Hoffmann
- ZeS, Abteilung Gesundheitsökonomie, Gesundheitspolitik und Versorgungsforschung, Universität Bremen, 28334, Bremen, Deutschland,
| | | |
Collapse
|
20
|
Rossow I, Bramness JG. The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study. BMC Public Health 2015; 15:288. [PMID: 25885781 PMCID: PMC4377902 DOI: 10.1186/s12889-015-1615-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2013] [Accepted: 03/05/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Prescription drug sales may vary considerably across regions and over time. This study aimed to assess whether there is an association between mean drug sales and prevalence of excessive use in a range of psychotropic prescription drugs with an abuse potential, and if so, whether the variation in mean drug sales mostly reflects variation in the prevalence of excessive use or mostly reflects variation in non-excessive use. METHODS Data on all filled prescriptions taken from the Norwegian prescription database for 10 drugs with an abuse potential (pain relievers, anxiolytics, and hypnotics) during one calendar year (2005) in Norway (n = 4,053,624) included number of defined daily doses (DDD). These were aggregated to individual level (n = 815,836) and county level (n = 19). RESULTS Analyses of individual level data showed that the distribution of drug use was skewed; those who used more than 365 DDD per year accounted for almost half of the sales of both anxiolytics and hypnotics. At the county level, the mean sales per inhabitant and the prevalence of excessive users were closely correlated, but both prevalence of non-excessive use and prevalence of excessive drug use were associated with the county-wise variation in mean drug sales. CONCLUSION Despite a strong individual control of access to psychotropic drugs through health personnel' prescribing, a small proportion of users account for a large fraction of the sales of these drugs. The sales vary significantly between regions and this variation is closely associated with the prevalence of excessive users. This suggests that sales figures as such may be used as an indicator to monitor variations in excessive use between regions and over time, and to evaluate interventions targeting over-prescription and excessive use.
Collapse
Affiliation(s)
- Ingeborg Rossow
- Norwegian Institute for Alcohol and Drug Research (SIRUS), Øvre Slotts g 2b, P.O. Box 565, Sentrum, 0105, Oslo, Norway.
| | - Jørgen G Bramness
- Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway. .,Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
| |
Collapse
|
21
|
Alessi-Severini S, Bolton JM, Enns MW, Dahl M, Collins DM, Chateau D, Sareen J. Use of benzodiazepines and related drugs in Manitoba: a population-based study. CMAJ Open 2014; 2:E208-16. [PMID: 25485245 PMCID: PMC4251517 DOI: 10.9778/cmajo.20130076] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Despite their favourable toxicology profile, benzodiazepines and the related Z-drugs (zopiclone, zolpidem and zaleplon) have been associated with physiological tolerance, dependence and addiction. Evidence of harm (e.g., falls, motor vehicle collisions and cognitive disturbances) has been reported in older populations. The aim of this study was to determine the relation between users' characteristics and the use of benzodiazepines and Z-drugs in Manitoba over a 16-year period. METHODS This time-series analysis was based on prescription data from Apr. 1, 1996, to Mar. 31, 2012, obtained from the Drug Product Information Network database of Manitoba. We obtained sociodemographic information on benzodiazepine and Z-drug users from the Population Registry and determined changes in utilization rates over time using generalized estimating equations. RESULTS Overall, the prevalence of benzodiazepine use remained stable at about 61.0 per 1000 population between 1996/97 and 2011/12; however, the prevalence of Z-drug use increased steadily from 10.9 to 37.0 per 1000 over the same period. In older people (≥ 65 years), the incidence of benzodiazepine use decreased from 55.5 to 30.3 users per 1000, whereas the incidence of Z-drug use increased from 7.3 to 20.3 users per 1000 over the study period. Among those 18-64 years of age, the incidence of benzodiazepine use decreased from 30.1 to 27.6 users per 1000, but the increase in incidence of Z-drug use was more than 2-fold. The youngest population (≤ 17 years) showed the lowest rates of use of these drugs. The highest rates of use were observed among older women and the low-income population. INTERPRETATION Over the study period, benzodiazepines have been prescribed less frequently to older patients in Manitoba; however, zopiclone prescribing has continued to increase for all age groups. The reasons for this increase remain to be determined.
Collapse
Affiliation(s)
| | - James M. Bolton
- Department of Psychiatry, Faculty of Medicine, University of Manitoba, Winnipeg, Man
- Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, Man
- Department of Psychology, Faculty of Arts, University of Manitoba, Winnipeg, Man
| | - Murray W. Enns
- Department of Psychiatry, Faculty of Medicine, University of Manitoba, Winnipeg, Man
- Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, Man
- Department of Psychology, Faculty of Arts, University of Manitoba, Winnipeg, Man
| | - Matthew Dahl
- Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Man
| | | | - Dan Chateau
- Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, Man
- Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Man
| | - Jitender Sareen
- Department of Psychiatry, Faculty of Medicine, University of Manitoba, Winnipeg, Man
- Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, Man
- Department of Psychology, Faculty of Arts, University of Manitoba, Winnipeg, Man
| |
Collapse
|
22
|
Lin FY, Chen PC, Liao CH, Hsieh YW, Sung FC. Retrospective population cohort study on hip fracture risk associated with zolpidem medication. Sleep 2014; 37:673-9. [PMID: 24899758 DOI: 10.5665/sleep.3566] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
STUDY OBJECTIVE Few studies have evaluated the hip fracture risk for zolpidem users. We assessed the risk for subjects taking zolpidem. DESIGN Population-based retrospective cohort study using claims data of a universal insurance system. PARTICIPANTS We identified 6,978 patients newly prescribed for zolpidem in 2000-2001 age 18 y and older, and 27,848 nonusers frequency matched with sex, age, and date visiting a clinic. MEASUREMENTS AND RESULTS Both cohorts were followed up to the end of 2008 to measure the hip fracture incidence and risk, which considered factors such as sex, age, occupation, days of drug use, and osteoporosis status. The zolpidem users had a 2.23-fold higher hip fracture incidence than nonusers (3.10 versus 1.39 per 1,000 person-y). The risk increased with age for both cohorts. The elderly users had a 21-fold higher incidence than the younger users, or twofold higher than the elderly nonusers. Among 33 patients (20.4%) with hip fracture occurring during presumed medication days, which was accountable for an incidence of 1,083.0 per 1,000 person-y. Those taking the medicine for 8 days or longer had a moderately higher fracture rate than those taking it for less days (6.02 versus 4.48 per 100 person-times) with a ratio of 1.34 (95% confidence interval 0.42-4.56). Subjects with blue collar occupations were at a higher fracture risk. CONCLUSION The hip fracture risk of zolpidem users is higher than that of nonusers. Fracture prevention awareness should be disseminated to the users.
Collapse
Affiliation(s)
- Fang-Yu Lin
- Department of Public Health, China Medical University, Taichung, Taiwan ; Department of Epidemiology, University of Texas School of Public Health, Houston, TX
| | - Pei-Chun Chen
- Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan
| | - Chun Hui Liao
- Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan
| | - Yow-Wen Hsieh
- Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan
| | - Fung-Chang Sung
- Department of Public Health, China Medical University, Taichung, Taiwan
| |
Collapse
|
23
|
Holdø I, Handal M, Skurtveit S, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. Arch Dis Child 2013; 98:732-6. [PMID: 23845695 DOI: 10.1136/archdischild-2013-303646] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To describe the dispensing of the hypnotic alimemazine to children aged 0-3 years and investigate the association between dispensing of alimemazine to children and dispensed hypnotics to their parents. DESIGN An observational cohort study linking information from the Medical Birth Registry of Norway and the Norwegian Prescription Database. Hypnotics dispensed to parents in a 1-year period before pregnancy was associated with dispensed alimemazine for children aged 0-3 years. PATIENTS AND SETTING All children born in Norway in 2008 (N=59 325) and their mothers and fathers were included. MAIN OUTCOME MEASURES Dispensed alimemazine to children during the first 3 years of life. RESULTS Three percent of children received alimemazine. Dispensed hypnotics to mothers increased the risk of the child receiving a prescription for alimemazine, OR of 2.3 (1.7-3.0) for boys and 1.7 (1.2-2.4) for girls. When both parents had been dispensed prescriptions for hypnotics, the risk increased nearly threefold. A dispensed alimemazine prescription was also associated with dispensed prescriptions for antidepressants to both mother and father, mother's smoking, the child's gender and child's prescriptions for antibiotics, respiratory drugs and dermatological steroids. CONCLUSIONS Dispensed alimemazine to children under 3 was associated with parents' previous use of hypnotics, indicating that factors other than the child's health influence the use of hypnotic drugs in infancy and toddler years. The frequent usage of alimemazine in children below 3 years and the association with parents' use of hypnotics should concern prescribing doctors.
Collapse
Affiliation(s)
- Ingvild Holdø
- Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway.
| | | | | | | |
Collapse
|
24
|
Affiliation(s)
- Susanne Rösner
- Forel Klinik; Islikonerstrasse 5 Ellikon an der Thur Switzerland 8548
| | - Michael Soyka
- University of Munich; Psychiatric Hospital; Nußbaumstr. 7 Munich Germany 80336
| | - Göran Hajak
- Psychiatric Hospital; Psychiatry; Universitätsstraße 84 Regensburg Bavaria Germany 93053
| | - Renate Wehrle
- EasyCap; Steingrabenstr. 14 Herrsching Germany 82211
| | | |
Collapse
|
25
|
Affiliation(s)
- Susanne Rösner
- Forel Klinik; Islikonerstrasse 5 Ellikon an der Thur Switzerland 8548
| | - Michael Soyka
- University of Munich; Psychiatric Hospital; Nußbaumstr. 7 Munich Germany 80336
| | - Göran Hajak
- Psychiatric Hospital; Psychiatry; Universitätsstraße 84 Regensburg Bavaria Germany 93053
| | - Renate Wehrle
- EasyCap; Steingrabenstr. 14 Herrsching Germany 82211
| | | |
Collapse
|
26
|
Affiliation(s)
- Susanne Rösner
- Forel Klinik; Islikonerstrasse 5 Ellikon an der Thur Switzerland 8548
| | - Michael Soyka
- University of Munich; Psychiatric Hospital; Nußbaumstr. 7 Munich Germany 80336
| | - Göran Hajak
- Psychiatric Hospital; Psychiatry; Universitätsstraße 84 Regensburg Bavaria Germany 93053
| | - Renate Wehrle
- EasyCap; Steingrabenstr. 14 Herrsching Germany 82211
| | | |
Collapse
|
27
|
Affiliation(s)
- Susanne Rösner
- Forel Klinik; Islikonerstrasse 5 Ellikon an der Thur Switzerland 8548
| | - Michael Soyka
- University of Munich; Psychiatric Hospital; Nußbaumstr. 7 Munich Germany 80336
| | - Göran Hajak
- Psychiatric Hospital; Psychiatry; Universitätsstraße 84 Regensburg Bavaria Germany 93053
| | - Renate Wehrle
- EasyCap; Steingrabenstr. 14 Herrsching Germany 82211
| | | |
Collapse
|
28
|
Jehle J, Ficker E, Wan X, Deschenes I, Kisselbach J, Wiedmann F, Staudacher I, Schmidt C, Schweizer PA, Becker R, Katus HA, Thomas D. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. Br J Pharmacol 2013; 168:1215-29. [PMID: 23061993 DOI: 10.1111/bph.12002] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2012] [Revised: 09/09/2012] [Accepted: 09/23/2012] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND AND PURPOSE Zolpidem, a short-acting hypnotic drug prescribed to treat insomnia, has been clinically associated with acquired long QT syndrome (LQTS) and torsade de pointes (TdP) tachyarrhythmia. LQTS is primarily attributed to reduction of cardiac human ether-a-go-go-related gene (hERG)/I(Kr) currents. We hypothesized that zolpidem prolongs the cardiac action potential through inhibition of hERG K(+) channels. EXPERIMENTAL APPROACH Two-electrode voltage clamp and whole-cell patch clamp electrophysiology was used to record hERG currents from Xenopus oocytes and from HEK 293 cells. In addition, hERG protein trafficking was evaluated in HEK 293 cells by Western blot analysis, and action potential duration (APD) was assessed in human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. KEY RESULTS Zolpidem caused acute hERG channel blockade in oocytes (IC(50) = 61.5 μM) and in HEK 293 cells (IC(50) = 65.5 μM). Mutation of residues Y652 and F656 attenuated hERG inhibition, suggesting drug binding to a receptor site inside the channel pore. Channels were blocked in open and inactivated states in a voltage- and frequency-independent manner. Zolpidem accelerated hERG channel inactivation but did not affect I-V relationships of steady-state activation and inactivation. In contrast to the majority of hERG inhibitors, hERG cell surface trafficking was not impaired by zolpidem. Finally, acute zolpidem exposure resulted in APD prolongation in hiPSC-derived cardiomyocytes. CONCLUSIONS AND IMPLICATIONS Zolpidem inhibits cardiac hERG K(+) channels. Despite a relatively low affinity of zolpidem to hERG channels, APD prolongation may lead to acquired LQTS and TdP in cases of reduced repolarization reserve or zolpidem overdose.
Collapse
Affiliation(s)
- J Jehle
- Department of Cardiology, Medical University Hospital, Heidelberg, Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Hoffmann F. Benefits and risks of benzodiazepines and Z-drugs: comparison of perceptions of GPs and community pharmacists in Germany. GERMAN MEDICAL SCIENCE : GMS E-JOURNAL 2013; 11:Doc10. [PMID: 23904824 PMCID: PMC3728643 DOI: 10.3205/000178] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Revised: 07/01/2013] [Indexed: 11/30/2022]
Abstract
Objective: Newer non-benzodiazepines zolpidem and zopiclone (“Z-drugs”) are often prescribed instead of benzodiazepine hypnotics, although there is no evidence of differences in effectiveness and safety. Aim was to compare perceptions on benefits and harms of benzodiazepines and Z-drugs between general practitioners (GPs) and community pharmacists (CPs). Methods: A questionnaire was mailed to a random sample of 1,350 GPs and 600 CPs in 2012. They were asked to rate perceptions on a five-point Likert scale used for both benzodiazepines and Z-drugs. Wilcoxon signed rank test was performed for the comparison of perceptions between GPs and CPs. Due to multiple testing, only p-values ≤0.01 were considered statistically significant. Results: 458 GPs and 202 CPs returned questionnaires (response 33.9% and 33.7%). Mean age of GPs was 53.3 years (40.6% female) and 48.8 years for CPs (59.2% females). Perceptions on benefits of benzodiazepines (and Z-drugs) between GPs and CPs were not different for 3 (and 2) of 5 items. Concerning side effects of benzodiazepines, there were no statistically significant differences for 3 of 5 comparisons. CPs perceived that 4 of 5 studied side effects of Z-drugs occur significantly more often than GPs (p=0.003 or less). For instance, whereas 45.2% of CPs answered that withdrawal effects on stopping happen often or very often/always on Z-drugs, these were only 28.3% of the GPs. Conclusions: Although it is difficult to draw unambiguous conclusions from these findings, pharmacists might have a somewhat more critical view on Z-drugs, especially concerning side effects.
Collapse
Affiliation(s)
- Falk Hoffmann
- University of Bremen, Centre for Social Policy Research, Division Health Economics, Health Policy and Outcomes Research, Bremen, Germany.
| |
Collapse
|
30
|
Hsiao FY, Hsieh PH, Gau CS. Ten-year trend in prescriptions of z-hypnotics among the elderly: A nationwide, cross-sectional study in Taiwan. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/j.jcgg.2012.12.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Couto ATR, Silva DT, Silvestre CC, Lyra DP, Quintans LJ. Quality analysis of research on the use of benzodiazepines by elderly patients in the emergency room:a systematic review. Eur J Clin Pharmacol 2013; 69:1343-50. [DOI: 10.1007/s00228-012-1439-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2012] [Accepted: 10/16/2012] [Indexed: 10/27/2022]
|
32
|
Handal M, Skurtveit S, Mørland JG. [Co-medication with benzodiazepines]. TIDSSKRIFT FOR DEN NORSKE LEGEFORENING 2012; 132:526-30. [PMID: 22398769 DOI: 10.4045/tidsskr.11.0321] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
BACKGROUND The various benzodiazepines have essentially the same mechanism of action and differ from one another primarily through differences in pharmacokinetics. There is no pharmacological basis for using more than one benzodiazepine for the same patient. The purpose of the study was to examine the occurence of co-medication with different types of benzodiazepines in Norway. MATERIAL AND METHOD Data were obtained from the Norwegian Prescription Database. Patients who received at least one benzodiazepine in 2008 were included (n = 299,185). The percentage of users who were co-medicated with at least two different benzodiazepines and the amounts prescribed were calculated and stratified by gender and age. RESULTS It is highly probably that 27,861 (14,6%) of patients who received at least two benzodiazepines in the course of 2008 used two different benzodiazepines simultaneously. 13,267 (6.9%) of the patients were prescribed at least two different benzodiazepines on the same prescription. A larger number of women were co-medicated with different benzodiazepines, but the proportion of comedication was higher in men than in women, and most frequent in the age group 18-49 years. INTERPRETATION There is an extensive and unfortunate prescription practice whereby the same patient is prescribed different benzodiazepines that are used concurrently. Patients who use different benzodiazepines concurrently are mainly prescribed these by one and the same doctor.
Collapse
Affiliation(s)
- Marte Handal
- Avdeling for legemiddelepidemiologi, Divisjon for epidemiologi, Nasjonalt folkehelseinstitutt, Norway.
| | | | | |
Collapse
|
33
|
Abstract
AIMS To re-examine various aspects of the benzodiazepines (BZDs), widely prescribed for 50 years, mainly to treat anxiety and insomnia. It is a descriptive review based on the Okey Lecture delivered at the Institute of Psychiatry, King's College London, in November 2010. METHODS A search of the literature was carried out in the Medline, Embase and Cochrane Collaboration databases, using the codeword 'benzodiazepine(s)', alone and in conjunction with various terms such as 'dependence', 'abuse', etc. Further hand-searches were made based on the reference lists of key papers. As 60,000 references were found, this review is not exhaustive. It concentrates on the adverse effects, dependence and abuse. RESULTS Almost from their introduction the BZDs have been controversial, with polarized opinions, advocates pointing out their efficacy, tolerability and patient acceptability, opponents deprecating their adverse effects, dependence and abuse liability. More recently, the advent of alternative and usually safer medications has opened up the debate. The review noted a series of adverse effects that continued to cause concern, such as cognitive and psychomotor impairment. In addition, dependence and abuse remain as serious problems. Despite warnings and guidelines, usage of these drugs remains at a high level. The limitations in their use both as choice of therapy and with respect to conservative dosage and duration of use are highlighted. The distinction between low-dose 'iatrogenic' dependence and high-dose abuse/misuse is emphasized. CONCLUSIONS The practical problems with the benzodiazepines have persisted for 50 years, but have been ignored by many practitioners and almost all official bodies. The risk-benefit ratio of the benzodiazepines remains positive in most patients in the short term (2-4 weeks) but is unestablished beyond that time, due mainly to the difficulty in preventing short-term use from extending indefinitely with the risk of dependence. Other research issues include the possibility of long-term brain changes and evaluating the role of the benzodiazepine antagonist, flumazenil, in aiding withdrawal.
Collapse
Affiliation(s)
- Malcolm Lader
- Addiction Research Centre, Institute of Psychiatry, King's College London, London, UK.
| |
Collapse
|
34
|
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21:718-79. [PMID: 21924589 DOI: 10.1016/j.euroneuro.2011.08.008] [Citation(s) in RCA: 988] [Impact Index Per Article: 76.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND The spectrum of disorders of the brain is large, covering hundreds of disorders that are listed in either the mental or neurological disorder chapters of the established international diagnostic classification systems. These disorders have a high prevalence as well as short- and long-term impairments and disabilities. Therefore they are an emotional, financial and social burden to the patients, their families and their social network. In a 2005 landmark study, we estimated for the first time the annual cost of 12 major groups of disorders of the brain in Europe and gave a conservative estimate of €386 billion for the year 2004. This estimate was limited in scope and conservative due to the lack of sufficiently comprehensive epidemiological and/or economic data on several important diagnostic groups. We are now in a position to substantially improve and revise the 2004 estimates. In the present report we cover 19 major groups of disorders, 7 more than previously, of an increased range of age groups and more cost items. We therefore present much improved cost estimates. Our revised estimates also now include the new EU member states, and hence a population of 514 million people. AIMS To estimate the number of persons with defined disorders of the brain in Europe in 2010, the total cost per person related to each disease in terms of direct and indirect costs, and an estimate of the total cost per disorder and country. METHODS The best available estimates of the prevalence and cost per person for 19 groups of disorders of the brain (covering well over 100 specific disorders) were identified via a systematic review of the published literature. Together with the twelve disorders included in 2004, the following range of mental and neurologic groups of disorders is covered: addictive disorders, affective disorders, anxiety disorders, brain tumor, childhood and adolescent disorders (developmental disorders), dementia, eating disorders, epilepsy, mental retardation, migraine, multiple sclerosis, neuromuscular disorders, Parkinson's disease, personality disorders, psychotic disorders, sleep disorders, somatoform disorders, stroke, and traumatic brain injury. Epidemiologic panels were charged to complete the literature review for each disorder in order to estimate the 12-month prevalence, and health economic panels were charged to estimate best cost-estimates. A cost model was developed to combine the epidemiologic and economic data and estimate the total cost of each disorder in each of 30 European countries (EU27+Iceland, Norway and Switzerland). The cost model was populated with national statistics from Eurostat to adjust all costs to 2010 values, converting all local currencies to Euro, imputing costs for countries where no data were available, and aggregating country estimates to purchasing power parity adjusted estimates for the total cost of disorders of the brain in Europe 2010. RESULTS The total cost of disorders of the brain was estimated at €798 billion in 2010. Direct costs constitute the majority of costs (37% direct healthcare costs and 23% direct non-medical costs) whereas the remaining 40% were indirect costs associated with patients' production losses. On average, the estimated cost per person with a disorder of the brain in Europe ranged between €285 for headache and €30,000 for neuromuscular disorders. The European per capita cost of disorders of the brain was €1550 on average but varied by country. The cost (in billion €PPP 2010) of the disorders of the brain included in this study was as follows: addiction: €65.7; anxiety disorders: €74.4; brain tumor: €5.2; child/adolescent disorders: €21.3; dementia: €105.2; eating disorders: €0.8; epilepsy: €13.8; headache: €43.5; mental retardation: €43.3; mood disorders: €113.4; multiple sclerosis: €14.6; neuromuscular disorders: €7.7; Parkinson's disease: €13.9; personality disorders: €27.3; psychotic disorders: €93.9; sleep disorders: €35.4; somatoform disorder: €21.2; stroke: €64.1; traumatic brain injury: €33.0. It should be noted that the revised estimate of those disorders included in the previous 2004 report constituted €477 billion, by and large confirming our previous study results after considering the inflation and population increase since 2004. Further, our results were consistent with administrative data on the health care expenditure in Europe, and comparable to previous studies on the cost of specific disorders in Europe. Our estimates were lower than comparable estimates from the US. DISCUSSION This study was based on the best currently available data in Europe and our model enabled extrapolation to countries where no data could be found. Still, the scarcity of data is an important source of uncertainty in our estimates and may imply over- or underestimations in some disorders and countries. Even though this review included many disorders, diagnoses, age groups and cost items that were omitted in 2004, there are still remaining disorders that could not be included due to limitations in the available data. We therefore consider our estimate of the total cost of the disorders of the brain in Europe to be conservative. In terms of the health economic burden outlined in this report, disorders of the brain likely constitute the number one economic challenge for European health care, now and in the future. Data presented in this report should be considered by all stakeholder groups, including policy makers, industry and patient advocacy groups, to reconsider the current science, research and public health agenda and define a coordinated plan of action of various levels to address the associated challenges. RECOMMENDATIONS Political action is required in light of the present high cost of disorders of the brain. Funding of brain research must be increased; care for patients with brain disorders as well as teaching at medical schools and other health related educations must be quantitatively and qualitatively improved, including psychological treatments. The current move of the pharmaceutical industry away from brain related indications must be halted and reversed. Continued research into the cost of the many disorders not included in the present study is warranted. It is essential that not only the EU but also the national governments forcefully support these initiatives.
Collapse
|
35
|
Pressman MR. Sleep driving: Sleepwalking variant or misuse of z-drugs? Sleep Med Rev 2011; 15:285-92. [DOI: 10.1016/j.smrv.2010.12.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2010] [Revised: 12/16/2010] [Accepted: 12/16/2010] [Indexed: 10/18/2022]
|
36
|
Kjosavik SR, Ruths S, Hunskaar S. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2011; 68:311-9. [PMID: 21928085 DOI: 10.1007/s00228-011-1124-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2011] [Accepted: 08/30/2011] [Indexed: 11/29/2022]
Abstract
PURPOSE To examine (1) incidence rates for treatment with addictive anxiolytics and hypnotics in Norway, (2) the proportions initiated by general practitioners (GPs), psychiatrists, and other physicians, and (3) the course of the treatment among incident users during a 3.5 year follow-up period. METHOD Data on all prescriptions of anxiolytics (ATC code N05B) and hypnotics (N05C) dispensed to the general population from 1 January 2004 to 31 August 2009 were extracted from the Norwegian Prescription Database and merged with data about GPs from the Norwegian Regular General Practitioner Scheme. RESULTS One-year incidence rates per 1,000 inhabitants were 18.2 for anxiolytics, 24.5 for hypnotics, and 35.4 for anxiolytics and hypnotics combined. GPs and psychiatrists initiated the treatment to 75.4 and 2.4%, respectively. Only 30.8% received short-term treatment as recommended. Long-term use (11.8%) and heavy use (1.4%) were most common for treatments initiated by a GP, but the risk both of long-term and of heavy use was highest for patients initially treated by a psychiatrist. The amount redeemed during the first quarter was the strongest predictor of long-term use and of heavy use. However, even during the quarter with highest drug consumption, 81.5% of the patients received <1 DDD/day. CONCLUSIONS This study indicates that physicians' prescribing strategy towards initial users is crucial in order to prevent inappropriate drug use. There is a need to implement relevant guidelines and systems for structured clinical audits in general practice.
Collapse
Affiliation(s)
- Svein R Kjosavik
- Research Group for General Practice, Department of Public Health and Primary Health Care, University of Bergen, P.O. Box 7804, 5020, Bergen, Norway.
| | | | | |
Collapse
|
37
|
Psychomotor performance after intake of zopiclone compared with intake of ethanol: a randomized, controlled, double-blinded trial. J Clin Psychopharmacol 2011; 31:481-8. [PMID: 21694628 DOI: 10.1097/jcp.0b013e3182214be6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The sleep medicine zopiclone (eszopiclone) is commonly used in most Western countries. The focus on legislation for possible traffic-impairing nonalcohol drugs have caused a need for comparing traffic relevant behavior after intake of commonly used psychoactive drugs to blood alcohol concentrations (BACs). We aimed to compare psychomotor effects at 3 levels of behavior at different blood zopiclone concentrations to effects seen at different BACs. We performed a randomized double-blinded trial on 16 healthy volunteers who received either 10 or 5 mg zopiclone, 50 g ethanol or placebo in a crossover design. The volunteers performed computerized tests at baseline, 1, 3.5, and 6.5 hours after intake, accompanied by blood sampling. Impairment was found at all 3 behavior levels. For zopiclone, impairment was most pronounced at behavior level 1 (automotive behavior); a mean blood zopiclone concentration at 39 μg/L achieved 1 hour after intake of 10 mg zopiclone was accompanied by more impairment than BAC 0.074 %. At behavior levels 2 (control behavior) and 3 (executive planning), the psychomotor impairment accompanying approximately 39 μg/L zopiclone seemed comparable to a BAC of approximately 0.074%. No test components were impaired at 6.5 hours after intake.
Collapse
|
38
|
Hoffmann F, Hies M, Glaeske G. Regional variations of private prescriptions for the non-benzodiazepine hypnotics zolpidem and zopiclone in Germany. Pharmacoepidemiol Drug Saf 2010; 19:1071-7. [DOI: 10.1002/pds.2013] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
39
|
Abstract
Abstract Purpose. The use of benzodiazepines remains a source of controversy. Some prescribers believe that they are beneficial and espouse their use; others regard their risk:benefit ratio as too adverse for any but occasional use. This review considers these viewpoints based on the appropriate literature. Survey. The recent English-language literature relating to this topic was surveyed. The publications proved too heterogeneous for a formal meta-analysis, so a descriptive review is provided. Overview. Surveys of benzodiazepine use provide data mainly from the UK, Europe and North America. Prescribing patterns varied widely but long-term usage is common and sometimes the norm. Conclusions. Long-term prescription of benzodiazepines still takes place despite general warnings from the medical and other professions and drug regulatory bodies that long-term use is unjustified both from the lack of a systemic database establishing such efficacy and a large literature documenting the risks of long-term usage, such as dependence. The young and the old are particularly at risk. Continued monitoring is essential, but the regulatory authorities may need to take a more active role in curbing such undesirable practice.
Collapse
Affiliation(s)
- John Donoghue
- Medicines in Mental Health Ltd, Liverpool, UK, and School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, UK
| | | |
Collapse
|
40
|
Omvik S, Pallesen S, Bjorvatn B, Sivertsen B, Havik OE, Nordhus IH. Patient characteristics and predictors of sleep medication use. Int Clin Psychopharmacol 2010; 25:91-100. [PMID: 20071997 DOI: 10.1097/yic.0b013e328334e5e6] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The objective of this study was to investigate the characteristics of sleep medication users, and their satisfaction with treatment and subjective difficulty with quitting the drugs. A representative sample of 5000 adults in Norway was selected to participate in an epidemiologic study. The data were collected through a postal survey in which a total of 2645 (52.9%) participants responded. Weighted logistic regression was used to explore predictors for the drug pattern use. The prevalence of lifetime, current, and chronic use of sleep medications were 18.8, 7.9, and 4.2%. The use was associated with low socioeconomic status, older age, female sex, and frequent symptoms of sleep disorders, anxiety, and depression. Older age and low perceived control over sleep were the strongest predictors for use and difficulty in quitting sleep medications. Among responders who had ever used sleep medications, 80.3% would prefer a nonpharmacological treatment alternative. It is concluded that consumption of sleep medications is widespread in Norway, and that perception of control over sleep may play a significant role in the drug pattern use. Nonpharmacological treatment is to a small extent implemented in the health care sector.
Collapse
Affiliation(s)
- Siri Omvik
- Department of Clinical Psychology, University of Bergen, Bergen, Norway.
| | | | | | | | | | | |
Collapse
|
41
|
Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol Drug Saf 2010; 19:280-8. [DOI: 10.1002/pds.1899] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
42
|
Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions. Epilepsy Res 2009; 87:31-9. [PMID: 19679449 DOI: 10.1016/j.eplepsyres.2009.07.005] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2009] [Revised: 05/31/2009] [Accepted: 07/15/2009] [Indexed: 10/20/2022]
Abstract
PURPOSE The aim of the study was to quantify the use of antiepileptic drugs (AEDs) in epilepsy and other indications in a nation-wide population using a prescription database. MATERIALS AND METHODS Prescription data of AEDs were collected from the Norwegian Prescription Database for the period 2004-2007, including 5.1 million prescriptions from 144,653 patients, all having at least one prescribed and dispensed AED. Diagnosis-related reimbursement codes were used as indicators for clinical use. RESULTS Of the AEDs used, 71% was in epilepsy, 15% in psychiatry, 13% in neuropathic pain, and <1% in migraine, trigeminus neuralgia and cancer adjuvance. The use in epilepsy increased steadily from 7.0 to 7.5 DDDs/1000 inhabitants/day (7%) from 2004 to 2007. The use of AEDs in other indications increased considerably more from 2004 to 2007: Neuropathic pain to 1.40 DDDs/1000 inhabitants/day (360%), psychiatry to 1.59 (200%), and migraine to 0.005 (642%). The prevalence of AED users increased and in 2007 it was 0.97% in epilepsy, 0.8% in neuropathic pain, 0.33% in psychiatry and 0.001% in migraine. In 2007, 49% of the AEDs used in epilepsy were a new drug, carbamazepine, lamotrigine and valproate being most frequently used. New AEDs were used in 96% in migraine prophylaxis, 94% in neuropathic pain, and 64% in psychiatry. CONCLUSIONS Based on a nation-wide prescription database, this study quantifies the wide and increasing use of AEDs, in particular the newer drugs.
Collapse
Affiliation(s)
- Cecilie Johannessen Landmark
- Department of Pharmacy, Faculty of Health Sciences, Oslo University College, Pilestredet 50, N-0167 Oslo, Norway.
| | | | | | | |
Collapse
|
43
|
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiol Drug Saf 2009. [DOI: 10.1002/pds.1651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
44
|
Gustavsen I, Al-Sammurraie M, Mørland J, Bramness JG. Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers. ACCIDENT; ANALYSIS AND PREVENTION 2009; 41:462-466. [PMID: 19393793 DOI: 10.1016/j.aap.2009.01.011] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/12/2008] [Revised: 12/05/2008] [Accepted: 01/27/2009] [Indexed: 05/27/2023]
Abstract
BACKGROUND About 3-7% of the adult population receives prescribed hypnotics. The benzodiazepine-like hypnotics, zopiclone and zolpidem, are the most commonly prescribed and may cause traffic-relevant impairment similar to that found for benzodiazepines. We investigated the relationship between blood zopiclone and zolpidem concentrations and driving impairment, as assessed by the clinical test for impairment. We compared these groups of drivers to a group suspected of alcohol-related impairment. METHODS Blood samples from suspected impaired drivers during 2000-2007, screened for approximately 25 possible impairing drugs with only one single drug detected, were studied in relation to the assessment of impairment. The 79 zopiclone positive drivers, the 43 zolpidem positive drivers, and the 3480 alcohol positive drivers were divided into groups depending on blood drug concentrations. RESULTS/DISCUSSION The proportion of drivers judged as impaired tended to increase the higher the blood zopiclone concentrations. Such a positive relationship was not found for zolpidem. For alcohol the proportion of impaired drivers was significantly related to blood alcohol concentrations (BACs). There were few drivers with low zopiclone or zolpidem concentrations included, which may have obscured any positive significant relationship. The percentage of impaired drivers among drivers with blood zopiclone concentrations above 130 microg/l roughly corresponded to the percentage of impaired drivers among drivers with BACs higher than 0.1%.
Collapse
Affiliation(s)
- Ingebjørg Gustavsen
- Norwegian Institute of Public Health, Division of Forensic Toxicology and Drug Abuse, PO Box 4404 Nydalen, 0403 Oslo, Norway.
| | | | | | | |
Collapse
|